The ASPECT2 Trial: A Phase 3, Randomized, Double-Blind Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Trial Profile

The ASPECT2 Trial: A Phase 3, Randomized, Double-Blind Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Apadenoson (Primary) ; Adenosine
  • Indications Coronary artery disease
  • Focus Diagnostic use
  • Acronyms ASPECT2
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 27 Aug 2014 New source identified and integrated (European Clinical Trials Database - EudraCT2011-001245-32).
    • 04 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top